Cancer-associated retinopathy in a patient with non-small-cell lung carcinoma

被引：22

作者：

Salgia, R

Hedges, TR

Rizk, M

Reimer, RH

Skarin, AT

机构：

[1] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, Dana Farber Canc Inst, Div Thorac Oncol Program, Boston, MA 02115 USA

[3] Harvard Univ, Sch Med, Boston, MA 02115 USA

[4] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA

[5] Waynesborough Ophthalmol, Goldsboro, NC 27534 USA

来源：

LUNG CANCER | 1998年 / 22卷 / 02期

关键词：

cancer-associated retinopathy; non-small-cell lung cancer; paraneoplastic syndrome; recoverin; autoimmune;

D O I：

10.1016/S0169-5002(98)00062-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Cancer-associated retinopathy (CAR) is a paraneoplastic syndrome most often associated with small-cell lung carcinoma (SCLC), and it has been reported in patients with other malignancies. Antibodies against recoverin, a 23-kDa protein, have been found in patients with CAR suggesting an autoimmune phenomenon. Herein is the first report of a patient with non-small-cell lung cancer (NSCLC) in whom anti-recoverin antibodies were detected in the serum. Steroid therapy, chemotherapy, and radiation therapy did not help the patient's vision. Progressive loss of vision in patients with lung cancer should, potentially, be tested for CAR. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.

引用

页码：149 / 152

页数：4

共 12 条

[1]

Adamus G, 1997, INVEST OPHTH VIS SCI, V38, P283

[2] The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy [J].